Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus

Cytokine

Volumn 33, Issue 6, 2006, Pages 337-345

  Baran Marszak, Fanny ^a,b   Laguillier, Christelle ^a   Youlyouz, Ibtissam ^c   Feuillard, Jean ^c   Mariette, Xavier ^a   Fagard, Remi ^b   Raphaël, Martine ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Apoptosis; B lymphocyte; Epstein Barr virus; Infliximab; Tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; INCUBATION TIME; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

HUMAN HERPESVIRUS 4;

EID: 33744526096     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.03.005     Document Type: Article

References (39)

1. Bernstein C.N., Blanchard J.F., Kliewer E., and Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
2. Georgescu L., Quinn G.C., Schwartzman S., and Paget S.A. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26 (1997) 794-804
3. Kamel O.W., Holly E.A., van de Rijn M., Lele C., and Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 26 (1999) 1676-1680
4. Kamel O.W., van de Rijn M., Hanasono M.M., and Warnke R.A. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 16 (1995) 363-368
5. Kumar S., Fend F., Quintanilla-Martinez L., Kingma D.W., Sorbara L., Raffeld M., et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 24 (2000) 66-73
6. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., and Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99 (2002) 3909-3915
7. Martin T., Weber J.C., Levallois H., Labouret N., Soley A., Koenig S., et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43 (2000) 908-916
8. Baecklund E., Ekbom A., Sparen P., Feltelius N., and Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317 (1998) 180-181
9. Nakatsuka S., Yao M., Hoshida Y., Yamamoto S., Iuchi K., and Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 20 (2002) 4255-4260
10. Kamel O.W., van de Rijn M., Weiss L.M., Del Zoppo G.J., Hench P.K., Robbins B.A., et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (1993) 1317-1321
11. Kamel O.W., Weiss L.M., van de Rijn M., Colby T.V., Kingma D.W., and Jaffe E.S. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 20 (1996) 1279-1287
12. Starzl T.E., Nalesnik M.A., Porter K.A., Ho M., Iwatsuki S., Griffith B.P., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
13. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
14. Natoli G., Costanzo A., Guido F., Moretti F., and Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 56 (1998) 915-920
15. Asso-Bonnet M., Feuillard J., Ferreira V., Bissieres P., Tarantino N., Korner M., et al. Relationship between IkappaBalpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells. Oncogene 17 (1998) 1607-1615
16. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
17. Catrina A.I., Trollmo C., af Klint E., Engstrom M., Lampa J., Hermansson Y., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52 (2005) 61-72
18. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
19. Feltelius N., Fored C.M., Blomqvist P., Bertilsson L., Geborek P., Jacobsson L.T., et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64 (2005) 246-252
20. Fleischmann R., and Yocum D. Does safety make a difference in selecting the right TNF antagonist?. Arthritis Res Ther 6 (2004) S12-S18
21. Baran-Marszak F., Feuillard J., Najjar I., Le Clorennec C., Bechet J.M., Dusanter-Fourt I., et al. Differential roles of STAT1{alpha} and STAT1{beta} in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 104 (2004) 2475-2483
22. Feuillard J., Gouy H., Bismuth G., Lee L.M., Debre P., and Korner M. NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Cytokine 3 (1991) 257-265
23. Wu F., Garcia J., Mitsuyasu R., and Gaynor R. Alterations in binding characteristics of the human immunodeficiency virus enhancer factor. J Virol 62 (1988) 218-225
24. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
25. Jelinek D.F., and Lipsky P.E. Regulation of human B lymphocyte activation, proliferation, and differentiation. Adv Immunol 40 (1987) 1-59
26. Heslop H.E., Bianchi A.C., Cordingley F.T., Turner M., Chandima W., De Mel C.P., et al. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 172 (1990) 1729-1734
27. Boussiotis V.A., Nadler L.M., Strominger J.L., and Goldfeld A.E. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 91 (1994) 7007-7011
28. Estrov Z., Kurzrock R., Pocsik E., Pathak S., Kantarjian H.M., Zipf T.F., et al. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med 177 (1993) 763-774
29. Laherty C.D., Hu H.M., Opipari A.W., Wang F., and Dixit V.M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267 (1992) 24157-24160
30. Lam N., and Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 15 (2003) 9-16
31. Cahir-McFarland E.D., Davidson D.M., Schauer S.L., Duong J., and Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 97 (2000) 6055-6060
32. Chen C., Edelstein L.C., and Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20 (2000) 2687-2695
33. Chen F., Castranova V., and Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 159 (2001) 387-397
34. Klein S.C., Kube D., Abts H., Diehl V., and Tesch H. Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leukemia Res 20 (1996) 633-636
35. Goldfeld A.E., Strominger J.L., and Doyle C. Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines. J Exp Med 174 (1991) 73-81
36. Baran-Marszak F., Fagard R., Girard B., Camilleri-Broet S., Zeng F., Lenoir G.M., et al. Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines. Lab Invest 82 (2002) 1463-1479
37. Gibbons D.L., Rowe M., Cope A.P., Feldmann M., and Brennan F.M. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol 24 (1994) 1879-1885
38. Munker R., DiPersio J., and Koeffler H.P. Tumor necrosis factor: receptors on hematopoietic cells. Blood 70 (1987) 1730-1734
39. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10 (2003) 45-65